Tami L Mark1. 1. Thomson Reuters, Washington, DC 20008, USA. Tami.mark@thomsonreuters.com
Abstract
BACKGROUND: Psychoactive medications, such as antidepressants, are one of the most widely prescribed categories of drugs in the US; yet few studies have comprehensively examined the conditions for which psychoactive medications are prescribed. To our knowledge, no prior study has examined the extent to which psychoactive medications are prescribed for non-psychiatric somatic illnesses or the main types of psychiatric disorders for which psychoactive medications are being used. OBJECTIVE: To examine the diagnoses for which psychiatric medications are being prescribed in the US by analysing data from a nationally representative survey of physicians. METHODS: The data were obtained from the 2005 National Disease and Therapeutic Index (NDTI), a continuing survey of a US office-based panel of physicians. The 2005 physician panel consisted of approximately 4000 physicians reporting quarterly, which was projected to a universe of 500,722 physicians. The study focused on the diagnoses that were given as the primary reason for prescribing the following types of psychotropic medications: antidepressants, antipsychotics and anti-anxiety medications. RESULTS: Of the total number of antidepressant drug mentions, 92.7% were prescribed for psychiatric conditions. The most common (65.3%) were mood disorders (e.g. depression), followed by anxiety disorders (16.4%), which together comprised 81.7% of all antidepressant drug mentions. Of the total number of anti-anxiety drug mentions, 67.7% were prescribed for psychiatric conditions. The most common diagnosis was anxiety disorders (comprising 39.6% of all drug mentions), followed by mood disorders (comprising 18.9% of all drug mentions). Almost one-third of anxiety medication drug mentions were for non-psychiatric conditions or conditions of unspecified type. Of the total number of antipsychotic drug mentions, 98.9% were prescribed for psychiatric conditions. The most common diagnoses, comprising 39.0% of all drug mentions, were mood disorders such as depression and bipolar disorder. The second most common psychiatric diagnosis was schizophrenia or other psychotic disorders, comprising 34.5% of drug mentions. Approximately 7.4% of drug mentions were for delirium, dementia, amnestic or other cognitive disorders. Attention-deficit/conduct/disruptive behaviour disorders were the diagnoses indicated on 5.7% of all antipsychotic drug mentions. Anxiety disorders were indicated on 5.5% of antipsychotic drug mentions. Disorders usually diagnosed in infancy/childhood/adolescence (e.g. autism) comprised 2.3% of antipsychotic drug mentions. CONCLUSIONS: This research provides a broad view of the nature of psychoactive medication prescribing, which may serve as a guide to future research, policy and education about these medications, their perceived benefits and risks, and their uses.
BACKGROUND: Psychoactive medications, such as antidepressants, are one of the most widely prescribed categories of drugs in the US; yet few studies have comprehensively examined the conditions for which psychoactive medications are prescribed. To our knowledge, no prior study has examined the extent to which psychoactive medications are prescribed for non-psychiatric somatic illnesses or the main types of psychiatric disorders for which psychoactive medications are being used. OBJECTIVE: To examine the diagnoses for which psychiatric medications are being prescribed in the US by analysing data from a nationally representative survey of physicians. METHODS: The data were obtained from the 2005 National Disease and Therapeutic Index (NDTI), a continuing survey of a US office-based panel of physicians. The 2005 physician panel consisted of approximately 4000 physicians reporting quarterly, which was projected to a universe of 500,722 physicians. The study focused on the diagnoses that were given as the primary reason for prescribing the following types of psychotropic medications: antidepressants, antipsychotics and anti-anxiety medications. RESULTS: Of the total number of antidepressant drug mentions, 92.7% were prescribed for psychiatric conditions. The most common (65.3%) were mood disorders (e.g. depression), followed by anxiety disorders (16.4%), which together comprised 81.7% of all antidepressant drug mentions. Of the total number of anti-anxiety drug mentions, 67.7% were prescribed for psychiatric conditions. The most common diagnosis was anxiety disorders (comprising 39.6% of all drug mentions), followed by mood disorders (comprising 18.9% of all drug mentions). Almost one-third of anxiety medication drug mentions were for non-psychiatric conditions or conditions of unspecified type. Of the total number of antipsychotic drug mentions, 98.9% were prescribed for psychiatric conditions. The most common diagnoses, comprising 39.0% of all drug mentions, were mood disorders such as depression and bipolar disorder. The second most common psychiatric diagnosis was schizophrenia or other psychotic disorders, comprising 34.5% of drug mentions. Approximately 7.4% of drug mentions were for delirium, dementia, amnestic or other cognitive disorders. Attention-deficit/conduct/disruptive behaviour disorders were the diagnoses indicated on 5.7% of all antipsychotic drug mentions. Anxiety disorders were indicated on 5.5% of antipsychotic drug mentions. Disorders usually diagnosed in infancy/childhood/adolescence (e.g. autism) comprised 2.3% of antipsychotic drug mentions. CONCLUSIONS: This research provides a broad view of the nature of psychoactive medication prescribing, which may serve as a guide to future research, policy and education about these medications, their perceived benefits and risks, and their uses.
Authors: Ahmed Elkashef; Frank Vocci; Marilyn Huestis; Margaret Haney; Alan Budney; Amanda Gruber; Nady el-Guebaly Journal: Subst Abus Date: 2008 Impact factor: 3.716
Authors: Maggie Nellissery; Richard S Feinn; Jonathan Covault; Joel Gelernter; Raymond F Anton; Helen Pettinati; Darlene Moak; Timothy Mueller; Henry R Kranzler Journal: Alcohol Clin Exp Res Date: 2003-09 Impact factor: 3.455
Authors: Carl Salzman; Dilip V Jeste; Roger E Meyer; Jiska Cohen-Mansfield; Jeffrey Cummings; George T Grossberg; Lissy Jarvik; Helena C Kraemer; Barry D Lebowitz; Katie Maslow; Bruce G Pollock; Murray Raskind; Susan K Schultz; Philip Wang; Julie M Zito; George S Zubenko Journal: J Clin Psychiatry Date: 2008-06 Impact factor: 4.384
Authors: Ahmed M Elkashef; Richard A Rawson; Ann L Anderson; Shou-Hua Li; Tyson Holmes; Edwina V Smith; Nora Chiang; Roberta Kahn; Frank Vocci; Walter Ling; Valerie J Pearce; Michael McCann; Jan Campbell; Charles Gorodetzky; William Haning; Barry Carlton; Joseph Mawhinney; Dennis Weis Journal: Neuropsychopharmacology Date: 2007-06-20 Impact factor: 7.853
Authors: Steven M Frenk; Sarah A Mustillo; Steven L Foy; Whitney D Arroyave; Elizabeth G Hooten; Kari H Lauderback; Keith G Meador Journal: Psychiatr Q Date: 2013-03
Authors: Yoichiro Takayanagi; Adam P Spira; O Joseph Bienvenu; Rebecca S Hock; Michelle C Carras; William W Eaton; Ramin Mojtabai Journal: J Clin Psychiatry Date: 2015-01 Impact factor: 4.384
Authors: Katherine A Lygrisse; Vivek Singh; Christian T Oakley; Alex Tang; Stephen G Zak; Andrew J Clair; Claudette M Lajam Journal: Arch Orthop Trauma Surg Date: 2022-03-23 Impact factor: 3.067
Authors: Alexander C Tsai; Nicholas Z Rosenlicht; Jon N Jureidini; Peter I Parry; Glen I Spielmans; David Healy Journal: PLoS Med Date: 2011-05-03 Impact factor: 11.069
Authors: Emma Björkenstam; Anders Hjern; Ellenor Mittendorfer-Rutz; Bo Vinnerljung; Johan Hallqvist; Rickard Ljung Journal: PLoS One Date: 2013-01-16 Impact factor: 3.240